Adenosine A2A receptor (ADORA2A) regulates inflammation, promotes tissue repair and collagen production by human dermal fibroblasts. We investigated the genetic polymorphisms of ADORA2A in susceptibility to systemic sclerosis (SSc). We genotyped 142 Korean SSc patients and 150 controls for polymorphisms of -1751A1C (rs5996696) and 1976C/T (rs5751876), to cover the promoter and all exon sequences of ADORA2A in Koreans, using TaqMan fluorogenic 5' nuclease assay and single base primer extension assay. Neither -1751A1C nor 1976CIT polymorphism showed difference in the distribution of alleles or genotypes between patients and controls with allele frequency of 89.9% v 91.0% for -1751A (p=0.64) and 56.5% v 54.0% for 1976C (p=0.55). Our findings suggest that the role of ADORA2A in SSc may not be genetically related.
Systemic sclerosis (SSc) is a rare autoimmune disease of unknown etiology which is characterized by progressive fibrosis of the skin and internal organs (1) . The pathogenesis of SSc has not been clearly identified, but endothelial dysfunction, Th2dominant immune dysregulation and tissue fibrosis have been suggested to be a pathway leading to SSc (2) . Adenosine is a product of ATP catabolism released from various cells under oxidative stress or hypoxia and acts as an important regulator of cellular function (3) (4) . Among the four G protein coupled receptors (GPRs) which adenosine interacts (AI, A2a, A2b, A3), A2A receptor is known to regulate inflammation, and promote tissue repair and collagen matrix production by human dermal fibroblasts (5) . Agonists of A2A receptor mediate angiogenesis and promote excisional wound closure (6) (7) . Furthermore, mice deficient in adenosine A2A receptor are protected from bleomycin-induced fibrosis, suggesting the role of A2A receptor in the pathogenesis of SSc (5) . Polymorphisms in adenosine A2A receptor gene (ADORA2A) have been related to neuropsychiatric diseases such as panic disorder (8) (9) , and anxiety responses (10) . Additionally, other studies have shown that variants of the ADORA2A gene are significantly associated with the development of aspirin-intolerant asthma (11) and protection from proliferative diabetic retinopathy in Type I diabetic patients (12) . Since adenosine A2A receptor plays a key role in the fibrosis process, we hypothesized that the polymorphisms of ADORA2A may be associated with susceptibility to SSc. To address this hypothesis, we compared single nucleotide polymorphisms of promoter and all exon sequences of ADORA2A gene in patients with SSc and healthy controls.
MATERIALS AND METHODS
A total of 142 patients who were diagnosed with SSc at Seoul National University Hospital between January, 1999 and June, 2007 were enrolled in the study. All the patients fulfilled the preliminary classification criteria of SSc according to the American College of Rheumatology (13) . The following variables were collected at enrollment; age at diagnosis, cutaneous subtype, autoantibody status, and major organ involvements. One hundred and fifty age-and sex-matched Korean healthy blood donors were included as controls. The Institutional Review Board of Seoul National University Hospital approved this study and informed consents were obtained from all patients and controls. We genotyped polymorphisms of -1751A/C (rs5996696) and 1976C/T (rs5751876), which represent major variations (minor allele frequencies> 5.0%) of the promoter and exon sequences of ADORA2A in Koreans, respectively (11) . Genotyping of -1751A/C and 1976C/T were performed with TaqMan f1uorogenic 5' nuclease assay (ABI, Foster City, CA, USA) and single base primer extension assay (ABI, Foster City, CA, USA), respectively. Haplotypes were estimated using UNPHASED, version 3.0.12 (MRC Biostatistics Unit, Cambridge, UK) (14) . Analysis of the data was performed for 138 patients (139 patients for 1976C/T) and 150 controls in whom genotyping was successfully performed.
RESULTS
The patients' mean age (±standard deviation) was 48.4±12.9 years and the number of female patients was 125 (88.0%). The proportion of diffuse and limited cutaneous subsets were 67 (47.2%) and 75 (52.8%) patients, respectively. Anti-topoisomerase I antibody was present in 82 (60.7%) and anticentromere antibody in 17 (11.9%) patients. The number of patients with interstitial lung disease, pulmonary hypertension or SSe-related kidney disease were 92 (64.1%), 26 (25.0%) and 2 (1.4%), respectively. Genotype data could be obtained from 138 SSc patients and 150 healthy controls. As summarized in Table I , there was no significant difference in the frequencies of-1751AlC genotypes or alleles between SSc and controls. Genotype or allele distributions of 1976C/T were also similar. Distributions of major haplotypes were not significantly different. Any clinical subset of patients investigated in the study (skin subset, anti-topoisomerase I antibody, anticentromere antibody, lung involvement, pulmonary hypertension or renal crisis) was not associated with either -1751A1C or 1976C/T polymorphisms.
DISCUSSION
This is the first study investigating the genetic polymorphisms of adenosine receptor in SSc. Despite the in vitro and in vivo evidence linking A2A receptor and SSc (5-7), we could not establish the association of A2A receptor gene polymorphisms with SSc in Koreans. The negative results of our study can be explained as follows. Firstly, the number of patients may not be sufficient to demonstrate the difference. However, over 12,000 patients would be needed to show the difference of 0.9% (in case of -1751A1C) with alpha error of 5% and beta error of 10%. Considering the rarity of SSc, such study would be impractical. Secondly, there might be ethnic differences in the genetic polymorphisms of ADORA2A. Genetic polymorphisms of connective tissue growth factor (CTGF) and protein tyrosine phosphatase, non-receptor type 22 (PTPN22) in SSc are representative examples in which the results of polymorphism studies were different depending on the ethnic groups (15) (16) (17) (18) . However, similar distribution of 1976C/T alleles between Koreans and Caucasians (0.54/0.56 v 0.49/0.51) suggests that contribution of ethnic difference might not play a critical role (19) . Thirdly, our patient group may not represent all the different features of SSc patients. For example, patients with anti-centromere antibody were only 10.6% in our patient group, while 60.7% of patients have anti-topoisomerase I antibody. Fourthly, genetic polymorphisms of adenosine receptors may not play an important role in the pathogenesis of SSc. We focused on the SNPs located in promoter and exons of the ADORA2A in this study. Therefore, it is still possible that some polymorphisms in intron sequences or their interactions can be associated with SSc.
In conclusion, we found no differences in the distributions of adenosine A2A receptor -1751A1C and 1976C/Tpolymorphisms in Korean SSc patients and healthy controls. Our results suggest that the role of adenosine A2A receptor may not be genetically determined in SSc.
